PHARMACOKINETIC PROFILE OF IOBITRIDOL

Iobitridol (Xenetix) is a new triiodinated monomer, nonionic, low-osmo lality contrast agent. Animal pharmacokinetic studies (rats, rabbits, dogs) and in vitro studies show that it is a marker of extracellular f luid, i.e. it is distributed in the interstitial space, it does not pe netrate into cells, it does not cross the healthy blood-brain barrier (BBB), it does not bind to proteins, and it is eliminated by glomerula r filtration without secretion or reabsorption. These characteristics determine its use as an urography and angiography contrast agent as we ll as the precautions necessary to be taken, which are classical for c ontrast agents of this classification, related to administration in pa thophysiologic populations (patients with renal failure, pregnant wome n or nursing mothers, neonates, etc.).